A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma

Trial Profile

A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs SCIB 1 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Scancell
  • Most Recent Events

    • 11 Jul 2017 5 year survival results published in the Media Release
    • 30 Jan 2017 Status changed from active, no longer recruiting to completed, as per a Scancell Holdings PLC media release.
    • 21 Jul 2016 According to a Scancell media release, the clinical trial material will be available in approximately 9-12 months to recommence dosing of patients in the long-term extension of the Phase.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top